Dose Optimisation of Stavudine for the Treatment of HIV Infection

Inclusion Criteria:

• Patient is male or female aged ≥18 years (upper limit of <65 years in India)

• Patient has a documented laboratory diagnosis of infection with HIV-1 (positiveenzyme-linked immunosorbent assay HIV-1 antibody test) at screening or from previousrecords

• Patient has a life expectancy of ≥2 years in the opinion of the investigator

• Patient has a plasma HIV-1 RNA level >1000 copies/mL

• Patient has a plasma CD4 count ≤ 350 cells/mm3 using standard flow cytometry.

• Patient has the following clinical chemistry and haematological laboratory results:

• Serum creatinine ≤1.5 mg/dL (133 μmol/L) and a calculated creatinine clearancelevel ≥60 mL/min according to the Cockcroft-Gault formula

• Serum alanine aminotransferase <5 × upper limit of normal (ULN)

• Serum aspartate aminotransferase <5 × ULN

• Serum lipase ≤1.5 × ULN

• Total bilirubin ≤1.5 mg/dL (25 μmol/L) unless felt by clinician to be due toGilbert syndrome

• Haemoglobin ≥7.0 g/dLAbsolute neutrophil count ≥500/mm3

• Platelet count ≥50 000/mm3.

• Female patients of childbearing potential, including those who are less than 2 yearspost-menopausal, must agree to, and comply with using a highly effective method ofbirth control (eg, barrier contraceptives [condom or diaphragm with a spermicidalgel], hormonal contraceptives [implants, injectable, combination oral contraceptives,transdermal patches, or contraceptive rings], intrauterine devices, or sexualabstinence) while participating in this study. In addition, all women of childbearingpotential must agree to continue to use birth control throughout the study until laststudy visit Women Not of Childbearing Potential are women who are postmenopausal orpermanently sterilised (e.g. tubal occlusion, hysterectomy, bilateral salpingectomy).

• Women of Childbearing Potential (WOCBP) - Any female who has experienced menarche anddoes not meet the criteria for "Women Not of Childbearing Potential".

• Patient has the ability to comprehend the full nature and purpose of the study, in theopinion of the investigator, including possible risks and side effects, to cooperatewith the investigator, to understand verbal and written instructions, and to complywith the requirements of the entire study

• Patient is informed of the full nature and purpose of the study, including possiblerisks and side effects, given ample time and opportunity to read and understand thisinformation, and sign and date the written informed consent before inclusion in thestudy

Exclusion Criteria:

• Patients who have previously received treatment with any form of antiretroviraltherapy, including preventing mother-to-child transmission regimens

• Patients who are taking and cannot discontinue the following prohibited concomitantmedications at least 1 week prior to the baseline visit and for the duration of thestudy period:

• Any agents with significant nephrotoxic potential

• Probenecid

• Systemic chemotherapy agents

• Drugs that have significant interactions with EFV other than rifampicinAdministration of any of the above medications should be discontinued at least 1week prior to the baseline visit and for the duration of the study period.

• Patients who are clinically unstable, in the investigator's opinion, should bestabilized prior to inclusion into this study and their baseline concomitantmedications should be stable for at least 1 month (30 days) prior to enrolment. Inaddition, investigators should not anticipate changing dose levels or medications forthe duration of the study. Patients who, in the investigator's opinion, requireHIV-related prophylaxis (such as cotrimoxazole) and/or other HIV-related treatments (e.g. treatment for oral thrush, tuberculosis, etc) and who, in the investigator'sopinion are clinically stable may have such treatment initiated or discontinued duringthe screening period. The 30-day waiting period will not apply to the latter.

• Patients who have a current history of drug or alcohol abuse that, in the opinion ofthe investigator, may be an impediment to patient adherence to the protocol

• Patients who have a medical history or evidence of gastrointestinal malabsorptionsyndrome, chronic nausea, or vomiting which may prevent patients receiving oralmedication

• Patients who have participated in a study with an investigational drug within 60 daysof screening or who are currently receiving treatment with any other investigationaldrug or device

• Patients who are hepatitis B surface antigen positive

• Patients with symptomatic peripheral neuropathies

• Female patients who are currently pregnant or breastfeeding

• Female patients desiring pregnancy during the next 2 years

• Patients who have a strong likelihood of relocating far enough to make access to thestudy site difficult